ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

  • Abstract Number: 1553 • ACR Convergence 2023

    Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

    Yeliz Yagiz Ozogul1, Sinem Nihal Esatoglu2, Murat Ozogul3, Osman Kizilkilic4, Yesim Ozguler5, Ugur Uygunoglu6, Vedat Hamuryudan2 and Gulen Hatemi2, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey

    Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
  • Abstract Number: 1584 • ACR Convergence 2023

    Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

    Arielle Mendel1, Hassan Behlouli2, Evelyne Vinet1, Jeffrey Curtis3 and Sasha Bernatsky2, 1McGill University Health Centre, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
  • Abstract Number: 2375 • ACR Convergence 2023

    Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7

    Shoichi Fukui1, Haruna Matsuo2, Kanako Kojima3, Shota Kurushima1, Tohru Michitsuji4, Yoshika Tsuji5, Toshimasa Shimizu3, Masataka Umeda3, Remi Sumiyoshi5, Takashi Igawa1, Tomohiro Koga5, Shin-ya Kawashiri1, Naoki Iwamoto1, Tomoki Origuchi1 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki City, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, 5Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan

    Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
  • Abstract Number: 2376 • ACR Convergence 2023

    Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis

    Teppei Hashimoto1, Kazuteru Noguchi2, Yuko Minagawa2, Takeo Abe2, Masao Tamura2, Tetsuya Furukawa1, Naoto Azuma2 and Kiyoshi Matsui1, 1Hyogo Medical University, Nishinomiya, Japan, 2Hyogo Medical University, School of Medicine, Nishinomiya, Japan

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease requiring complex management due to a lack of suitable biomarkers. Elevated or persistently positive…
  • Abstract Number: 2379 • ACR Convergence 2023

    A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy

    Sam Oh1, Sushmitha Inguva2, Pallavi Rane2 and Brian Tumminello3, 1Amgen, Inc., South San Francisco, CA, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Inc., San Juan Capistrano, CA

    Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation and necrosis of small- to medium-sized blood vessels, commonly affecting the…
  • Abstract Number: 0682 • ACR Convergence 2023

    Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients

    Gunter Assmann1, Christoph Rittich1, Frank Neumann2, Udo Kellner3, Ryszard Turkiewicz4, Joerg Radermacher5, Peter Lamprecht6 and Björn Tampe7, 1RUB University Hospital Minden - Rheumatology, Minden, Germany, 2Jose Carreras Center Saarland, Homburg, Germany, 3RUB University Hospital Minden - Pathology, Minden, Germany, 4RUB University Hospital Minden - Pulmonology, Minden, Germany, 5RUB University Hospital Minden - Nephrology, Minden, Germany, 6University Hospital Luebeck - Schleswig-Holstein, Luebeck, Germany, 7University Clinic department Goettingen - Nephrology, Goettingen, Germany

    Background/Purpose: The orally administered C5a receptor inhibitor avacopan is approved for the therapy of ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide and shows…
  • Abstract Number: 2380 • ACR Convergence 2023

    Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data

    Chan-Bum Choi1, Jung-Min Shin2, Nayeon Choi3 and Soorack Ryu3, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea

    Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
  • Abstract Number: 0684 • ACR Convergence 2023

    Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Ulrich Specks1, David Jayne2 and Peter Merkel3, 1Mayo Clinic, Rochester, MN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
  • Abstract Number: 2385 • ACR Convergence 2023

    Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

    Jon Idoate1, Morgane Mourguet1, Thomas Villeneuve1, Grégoire Prevot1, Laurent Guilleminault2, Ribes David1, Stan Faguer1, Antoine Huart1, Dominique Chauveau1, Laurent Alric1, Martin Michaud1, Laurent Sailler1, Sébastien De Almeida Chavez1, Emmanuelle Mouchon1, Olivier Lairez1 and Gregory Pugnet3, 1CHU Toulouse, Toulouse, France, 2Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 3CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France

    Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
  • Abstract Number: 0685 • ACR Convergence 2023

    Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial

    Duvuru Geetha1, Anisha Dua2, Huibin Yue3, Carlo Salvarani4, David Jayne5 and Peter Merkel6, 1Johns Hopkins University, Baltimore, MD, 2Northwestern University, Chicago, IL, 3Amgen, Inc., Thousand Oaks, CA, 4Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
  • Abstract Number: 2492 • ACR Convergence 2023

    The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

    Rula Hajj-Ali1, Chao Zhang2, Renee Borchin3, Jenn Gordon4, David Cuthbertson3, Carol McAlear5, Christine Yeung5, David Badenoch6, Cristina Burroughs3 and Peter Merkel5, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3University of South Florida, Tampa, FL, 4Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA

    Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…
  • Abstract Number: 0686 • ACR Convergence 2023

    Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

    David Jayne1, Duvuru Geetha2, Christian Pagnoux3, Sebastian Sattui4 and Peter Merkel5, 1University of Cambridge, Cambridge, United Kingdom, 2Johns Hopkins University, Baltimore, MD, 3Mount Sinai Hospital, Toronto, ON, Canada, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Older adults are at increased risk of glucocorticoid (GC)-related toxicity; minimization of GCs is a major focus for treatment of patients with ANCA-associated vasculitis…
  • Abstract Number: 0689 • ACR Convergence 2023

    Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2

    Bryce Barr, Kim Cheema, Aurore Fifi-Mah, Stephanie Garner, Louis Girard and Jeffrey Ma, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Glomerulonephritis represents a severe manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and is associated with substantial morbidity and mortality. Therefore, maximal recovery…
  • Abstract Number: 0690 • ACR Convergence 2023

    Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy

    Dario Roccatello1, Savino Sciascia2, SILVIA GRAZIETTA FODDAI3, gIACOMO QUATTROCCHIO4, MASSIMO RADIN3, IRENE CECCHI3, ALICE BARINOTTI3, ELENA RUBINI3, MICHELA FERRO4, EMANUELE DE SIMONE4, carla naretto4, ANTONELLA BARRECA5, ANDREA SAMMARTINO4, DANIELA ROSSI4 and ROBERTA FENOGLIO4, 1University of Torino, Torino, Italy, 2University of Turin, Torino, Italy, 3University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, 4University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, 5Pathology Unit, Città della Salute e della Scienza, Turin, Italy

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in…
  • Abstract Number: 0703 • ACR Convergence 2023

    Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis

    Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA

    Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology